WHO WE ARE
Since its establishment in Suwon, Gyeonggi-do, Korea in 2016, Onegene Biotechnology has been developing the proprietary long-acting multi-ligand presenting platform that overcomes practical limitations in the development of therapeutics with more than three ligands.
By its effective use, we develop multi-targeting therapeutics for complex diseases such as metabolic, inflammatory diseases, and cancer. We envision that our technology opens a new path in the treatment of complex chronic diseases.
The Onegene Biotechnology's platform adopts an exceptionally efficient protein conjugation technology, which post-translationally connects two separately produced proteins.
Onegene’s robust post-translational fusion technology overcomes the fundamental issues in developing multi-targeting protein therapeutics such as intrinsic thermodynamic limitations, manufacturability challenges, and plug-and-play easiness.
#204 & 205, Ace Gwanggyotower2,
91 Changnyong-daero 256beon-gil,
Gyeonggi-do, Republic of Korea